Seragon touts promising preclinical lifespan and healthspan data in mice

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Treated mice had increased expression of longevity-associated genes and enhanced endurance and reduced frailty scores compared with controls.

Mysterious longevity biotech Seragon Biosciences is claiming significant results in a preclinical study of its “anti-aging candidate” known only as SRN-901. The Irvine, California-based biopharma quietly issued a press release earlier this week indicating that its 300-mouse study demonstrated “one of the largest extensions of lifespan and healthspan to date” in treated animals.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LT Staff

Longevity.Technology's in-house writing staff.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oura spends $625m to put doctors behind its smart ring

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE